Highlights

  • Mesoblast (ASX:MSB) shares increased 0.49% to AUD 2.05 during the morning session on 30 July 2026 after releasing its Q4 FY26 activity update.
  • RYONCIL generated US$36 million in net revenue during Q4 FY26, taking first full-year post-FDA approval revenue to US$115 million.
  • The company achieved its target of at least 300 patients treated in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.
  • Mesoblast reported US$103 million in cash as at 30 June 2026 after drawing US$50 million from its existing five-year facility.
  • The company continues expanding RYONCIL development into additional inflammatory disease indications, including adult SR-aGvHD.

Mesoblast Limited (ASX:MSB) shares edged 0.49% higher to AUD 2.05 during the morning session on 30 July 2026 after the biotechnology company released its activity report for the quarter ended 30 June 2026.

The latest update highlighted continued commercial progress for RYONCIL, with the company reporting US$36 million in net revenue for the fourth quarter and US$115 million in revenue during its first full year following FDA approval.

The share price movement came as Mesoblast provided updates across its commercial, clinical and financial activities, including expansion plans for RYONCIL, progress in the rexlemestrocel-L program and its latest cash position.

Although Mesoblast shares remain down 16.33% over the past year, the company’s latest quarterly update highlighted continued development across its cellular medicine portfolio and progress toward additional product opportunities.

Mesoblast Advances Commercialisation of Cellular Medicine Portfolio

Mesoblast is a global biotechnology company focused on developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions.

The company’s proprietary mesenchymal lineage cell therapy platform is designed to address excessive inflammation by releasing anti-inflammatory factors that help regulate multiple components of the immune system.

Mesoblast’s leading commercial product, RYONCIL (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy and is approved for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.

The company is also advancing additional applications for RYONCIL and developing rexlemestrocel-L programs targeting conditions including chronic low back pain and heart failure.

RYONCIL Revenue Growth Highlights First Full Year After FDA Approval

A key focus of Mesoblast’s Q4 FY26 update was the commercial performance of RYONCIL.

The company reported RYONCIL net revenue of US$36 million for the fourth quarter, contributing to total revenue of US$115 million during the first full year following FDA approval.

Revenue during the second half of FY26 reached US$66.5 million, reflecting continued commercial uptake of the therapy.

Mesoblast stated that RYONCIL adoption has continued across major U.S. pediatric centres for children with life-threatening steroid-refractory acute GvHD.

The company is now working to expand the approved label beyond pediatric patients by progressing development in adults with SR-aGvHD, a market that Mesoblast estimates is approximately three times larger than the current pediatric opportunity.

The registration trial for RYONCIL label expansion into adults with SR-aGvHD has commenced and is currently enrolling patients.

Mesoblast expects up to 40 sites across the United States to be activated during the year, representing approximately 60% of the estimated 8,500 annual U.S. allogeneic adult bone marrow transplant population.

RYONCIL Development Expands Across Additional Inflammatory Conditions

Beyond adult SR-aGvHD, Mesoblast continues exploring additional opportunities for RYONCIL across severe inflammatory diseases.

During the quarter, the company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to proceed directly to a registrational trial evaluating RYONCIL in ambulatory children aged five to nine years with Duchenne muscular dystrophy (DMD).

DMD is a rare genetic disorder affecting approximately 15,000 children in the United States, according to Mesoblast.

The company continues to evaluate opportunities to expand RYONCIL’s potential applications while progressing regulatory and clinical activities.

Rexlemestrocel-L Program Reaches Important Phase 3 Milestone

Mesoblast also reported progress in its rexlemestrocel-L development program.

The company achieved its target of treating at least 300 patients in the MSB-DR004 pivotal Phase 3 randomised controlled trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.

Patients enrolled in the study will continue to be followed through the trial’s 12-month primary endpoint, which will assess changes in pain levels from baseline between rexlemestrocel-L and placebo-treated groups.

The company also received a Biologics License Application (BLA) filing number from the FDA and requested a modular review of its BLA for rexlemestrocel-L in preventing life-threatening gastrointestinal bleeding caused by right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).

Financial Position Supported by Commercial Revenue and Funding Facility

Mesoblast reported US$103 million in cash as at 30 June 2026.

During the quarter, the company drew down US$50 million from its existing five-year facility to extinguish all maturing debt obligations.

The company’s quarterly cash flow report showed net operating cash spend of US$43.8 million for the full year, while operating cash spend during the second half was US$13.4 million.

For the June quarter, Mesoblast reported net cash used in operating activities of US$9.25 million.

The company ended the quarter with cash and cash equivalents of US$102.9 million, including US$47.4 million in bank balances and US$55.5 million in term deposits.

The available cash position provides funding support as Mesoblast continues progressing commercial activities, clinical programs and research initiatives.

Research and Development Activities Continue Across Cell Therapy Platform

Mesoblast continues investing in its broader cellular medicine technology platform.

During its inaugural R&D Day held in April 2026, the company announced next-generation mesenchymal stromal cell strategies, including the acquisition of an exclusive worldwide licence to a patented chimeric antigen receptor (CAR) technology platform.

The CAR technology provides Mesoblast with an opportunity to develop precision-enhanced therapeutic MSC products.

The company plans to explore CAR-MSC applications in inflammatory conditions including ulcerative colitis and Crohn’s disease.

Mesoblast also plans to use CAR-MSC technology expressing CD19 on their surface to investigate potential applications in Lupus Nephritis and other B-cell autoimmune diseases.

Corporate Progress and Intellectual Property Base

Mesoblast continues to maintain a broad intellectual property portfolio supporting its cellular medicine programs.

The company has more than 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions, manufacturing methods and therapeutic indications.

These intellectual property rights provide commercial protection extending through to at least 2044 across major markets.

The company also maintains commercial partnerships across Japan, Europe and China.

Mesoblast operates across Australia, the United States and Singapore and is listed on both the Australian Securities Exchange and Nasdaq.

Management Focuses on Expanding Product Opportunities

Mesoblast Chief Executive Dr Silviu Itescu highlighted the company’s focus on expanding RYONCIL adoption following its first full year of commercial launch.

The company stated that continued uptake across major U.S. pediatric centres positions RYONCIL for potential future expansion into adult SR-aGvHD.

Management also highlighted the importance of disciplined capital allocation as Mesoblast continues working toward additional clinical and regulatory milestones.

The company remains focused on advancing key programs, including RYONCIL expansion opportunities and rexlemestrocel-L development.

What This Means for Investors?

Mesoblast’s Q4 FY26 update highlighted continued progress across its commercial and clinical pipeline.

The company’s first full year of RYONCIL commercialisation generated US$115 million in net revenue, while ongoing label expansion programs could broaden future applications for the therapy.

Investors are likely to continue monitoring RYONCIL adoption, progress across rexlemestrocel-L trials and Mesoblast’s ability to advance additional cellular medicine opportunities.

With US$103 million in cash at the end of June 2026 and multiple clinical programs underway, the company enters the next period focused on expanding its commercial base and achieving further development milestones.

Answer: Mesoblast (ASX:MSB) shares increased 0.49% during the morning session after the company reported Q4 FY26 activity updates, including US$36 million in RYONCIL revenue and progress across its clinical development programs.

Answer: RYONCIL generated US$115 million in net revenue during its first full year following FDA approval, including US$36 million in the fourth quarter and US$66.5 million during the second half of FY26.

Answer: Mesoblast achieved its target of at least 300 patients treated in the pivotal Phase 3 MSB-DR004 trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.

Answer: Mesoblast reported US$103 million in cash as at 30 June 2026 after drawing down US$50 million from its existing five-year facility to extinguish maturing debt obligations.

Answer: Mesoblast is progressing RYONCIL development beyond pediatric SR-aGvHD into adult SR-aGvHD and is also evaluating potential applications in other severe inflammatory conditions, including Duchenne muscular dystrophy.